Cantor specialty pharma analyst to hold an analyst/industry conference call » 09:0101/2101/21/20
IMMU, SGEN, MGNX, PBYI, RHHBY, ARVN
Large Cap & Specialty…
Large Cap & Specialty Pharmaceuticals Analyst Chen, along with Key Opinion Leader Timothy Pluard, Medical Director of Saint Luke's Cancer Institute, discuss the 2020 outlook in breast cancer and potential approvals in TNBC (Triple-Negative Breast Cancer) and HER2+ (Human Epidermal Growth Factor Receptor 2) on an Analyst/Industry conference call to be held on January 27 at 11 am.
Cantor Fitzgerald healthcare analyst to hold analyst/industry conference call » 08:4801/2101/21/20
VRTX, BMRN, ALNY, ACAD, TGTX, BHVN, ARVN, IMMU, MRNS, CARA, KDMN, MGNX, MBIO
Healthcare Analyst Young…
Healthcare Analyst Young discusses the industry's outlook for 2020 and Top Picks for Large Cap Biotech, VRTX and BMRN; Mid-Cap Biotech, ALNY & ACAD, Small-Cap Biotech TGTX, BHVN, ARVN & IMMU; Micro-Cap Biotech, MRNS, CARA, KDMN, MGNX & MBIO on an Analyst/Industry conference call to be held on January 21 at 10 am.
|Over a week ago|
MacroGenics focused on extending cash runway through 2021 » 16:4201/0901/09/20
The company's estimated cash, cash equivalents and marketable securities balance as of December 31, 2019 was approximately $215M, compared to $232.9M as of December 31, 2018. Through the prioritization of programs and ongoing realignment of its resources, as well as anticipated and potential collaboration payments, MacroGenics is focused on extending its cash runway through 2021. The company will provide further guidance in connection with reporting Q4 and company progress in late February 2020.
MacroGenics discontinues MGD009, MGD007 programs » 16:4001/0901/09/20
MGD009 is a B7-H3 x CD3…
MGD009 is a B7-H3 x CD3 DART molecule and MGD007 is a gpA33 x CD3 DART molecule. In connection with its strategic prioritization, the company will discontinue development of these programs.
MacroGenics announces corporate, program priorities for 2020 » 16:3901/0901/09/20
MacroGenics announced its…
MacroGenics announced its corporate and program priorities for 2020. "Following the submission in 2019 of our first BLA with the FDA, 2020 has the potential to be a transformative year for MacroGenics. As the product candidates in our deep pipeline enter later-stage clinical trials, we are prioritizing certain programs in order to efficiently utilize our financial, human and intellectual capital on programs with the highest commercial and scientific merit and the potential to achieve regulatory approval," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. These include: Margetuximab, an Fc-engineered, anti-HER2 monoclonal antibody being evaluated for the treatment of patients with advanced HER2-positive cancers. Pending acceptance and review of the BLA submitted in December 2019 to the FDA based on the Phase 3 SOPHIA study results, the company anticipates a PDUFA date by the end of 2020. MacroGenics expects a Standard Review process in which the FDA will likely require an Oncologic Drugs Advisory Committee meeting in the second half of 2020. MacroGenics is enrolling patients in this front-line study designed to evaluate the combination of margetuximab with anti-PD-1 based therapies. Initial safety and efficacy data are expected in the second half of 2020 from Module A of this study, which is evaluating a chemotherapy-free regimen. Flotetuzumab is a bispecific CD123 x CD3 DART molecule being evaluated for the treatment of patients with relapsed or refractory acute myeloid leukemia. MacroGenics intends to define a potential registration path in the U.S. for the treatment of patients with primary induction failure and early relapsed AML in the first half of 2020, pending continued discussions with the FDA.
MacroGenics files to sell $50M in common stock » 17:0401/0301/03/20
Cowen acted as sole book…
Cowen acted as sole book running manager for the offering.
|Over a month ago|
MacroGenics files $250M mixed securities shelf 16:3512/2312/23/19
MacroGenics submits BLA for margetuximab to FDA » 12:0212/1912/19/19
MacroGenics announced that the company has submitted a Biologics License Application, or BLA, for margetuximab, an investigational, Fc-engineered, monoclonal antibody that targets HER2. The margetuximab BLA is for the treatment of patients with metastatic HER2-positive breast cancer in combination with chemotherapy. The submission is based on the safety and efficacy results of the pivotal phase 3 SOPHIA study, which were first presented at the 2019 American Society of Clinical Oncology annual meeting, with updated data recently presented at the 2019 San Antonio Breast Cancer Symposium.
Fly Intel: Top five analyst initiations » 10:0912/1912/19/19
CRK, MGNX, REAL, MMX, TACT
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Comstock Resources (CRK) initiated with a Neutral at MKM Partners. 2. MacroGenics (MGNX) initiated with an Overweight at Cantor Fitzgerald. 3. RealReal (REAL) initiated with a Buy at Needham. 4. Maverix Metals (MMX) initiated with an Outperformer at CIBC. 5. Transact Technologies (TACT) resumed with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Cantor starts MacroGenics with Overweight rating, $17 price target » 06:4712/1912/19/19
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Varun Kumar last night initiated coverage of MacroGenics with an Overweight rating and $17 price target. The shares have recently traded based on prospects for the company's lead asset margetuximab in HER2+ breast cancer, Kumar tells investors in a research note. However, he believes the narrative "needs to now change" as the market appears to underappreciate a "partially de-risked" asset in flotetuzumab and MacroGenics' "attractive pipeline optionality."